tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ARVN Stock Latest News

Arvinas and Pfizer’s FDA Nod for Cancer Drug
Company AnnouncementsArvinas and Pfizer’s FDA Nod for Cancer Drug
9d ago
8K
ARVN
Arvinas, Pfizer announce FDA acceptance of vepdegestrant NDA
PremiumThe Fly
Arvinas, Pfizer announce FDA acceptance of vepdegestrant NDA
9d ago
PFE
ARVN
Arvinas Holding’s Strategic Uncertainties and Partnership Challenges Justify Hold Rating
PremiumRatings
Arvinas Holding’s Strategic Uncertainties and Partnership Challenges Justify Hold Rating
9d ago
ARVN
Arvinas price target raised to $24 from $18 at H.C. Wainwright
PremiumThe Fly
Arvinas price target raised to $24 from $18 at H.C. Wainwright
10d ago
ARVN
Arvinas price target lowered to $16 from $19 at Wells Fargo
PremiumThe Fly
Arvinas price target lowered to $16 from $19 at Wells Fargo
10d ago
PFE
ARVN
Arvinas Holding Company: Strong Cash Position and Promising Pipeline Justify Buy Rating
PremiumRatingsArvinas Holding Company: Strong Cash Position and Promising Pipeline Justify Buy Rating
10d ago
ARVN
Arvinas Reports Q2 2025 Financials and Drug Developments
Premium
Company Announcements
Arvinas Reports Q2 2025 Financials and Drug Developments
10d ago
ARVN
Arvinas Earnings Call: Balancing Progress and Challenges
Premium
Company Announcements
Arvinas Earnings Call: Balancing Progress and Challenges
11d ago
ARVN
Arvinas Holding Company: Hold Rating Amid Modest Data and Strategic Uncertainties
PremiumRatings
Arvinas Holding Company: Hold Rating Amid Modest Data and Strategic Uncertainties
11d ago
ARVN
Arvinas reports Q2 EPS (84c), consensus (89c)
PremiumThe Fly
Arvinas reports Q2 EPS (84c), consensus (89c)
11d ago
ARVN
Arvinas sees cash runway into 2H28
PremiumThe Fly
Arvinas sees cash runway into 2H28
11d ago
ARVN
Arvinas announces retirement of CEO John Houston
PremiumThe Fly
Arvinas announces retirement of CEO John Houston
1M ago
ARVN
Arvinas Elects New Directors and Ratifies Auditor
PremiumCompany AnnouncementsArvinas Elects New Directors and Ratifies Auditor
2M ago
8K
ARVN
Arvinas Unveils Promising ARV-393 Data at EHA Congress
Premium
Company Announcements
Arvinas Unveils Promising ARV-393 Data at EHA Congress
2M ago
8K
ARVN
Arvinas presents preclinical data from studies of ARV-393
Premium
The Fly
Arvinas presents preclinical data from studies of ARV-393
2M ago
ARVN
Arvinas R&D President Ian Taylor Resigns
PremiumCompany Announcements
Arvinas R&D President Ian Taylor Resigns
2M ago
8K
ARVN
Arvinas and Pfizer Submit New Drug Application
PremiumCompany Announcements
Arvinas and Pfizer Submit New Drug Application
2M ago
8K
ARVN
Arvinas announces submission of NDA to FDA for vepdegestrant
PremiumThe Fly
Arvinas announces submission of NDA to FDA for vepdegestrant
2M ago
PFE
ARVN
Positive Buy Rating for Arvinas Holding Company Driven by Promising VERITAC-2 Trial Results and Strategic Partnership with Pfizer
PremiumRatings
Positive Buy Rating for Arvinas Holding Company Driven by Promising VERITAC-2 Trial Results and Strategic Partnership with Pfizer
3M ago
ARVN
Promising Phase 3 Results and Strategic Partnerships Drive Buy Rating for Arvinas
PremiumRatingsPromising Phase 3 Results and Strategic Partnerships Drive Buy Rating for Arvinas
3M ago
ARVN
Arvinas-Pfizer partnership dynamics may shift, says H.C. Wainwright
Premium
The Fly
Arvinas-Pfizer partnership dynamics may shift, says H.C. Wainwright
3M ago
PFE
ARVN
Buy Rating Justified by Arvinas Holding’s Promising Early-Stage Pipeline Despite Modest Trial Results
Premium
Ratings
Buy Rating Justified by Arvinas Holding’s Promising Early-Stage Pipeline Despite Modest Trial Results
3M ago
ARVN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >